Tofogliflozin hydrate (CSG-452 hydrate)

A potent inhibitor of SGLT2

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
2mg

￥637.00

510.00

- +
5mg

￥1087.00

870.00

- +
10mg

￥1612.00

1290.00

- +
50mg

￥5675.00

4540.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce46996
CAS: 1201913-82-7
别名: 托格列净,CSG-452 hydrate
分子式: C22H28O7
分子量: 404.45
纯度: >98%
溶解度: DMSO : ≥ 100 mg/mL (247.25 mM);Water : 0.33 mg/mL (0.82 mM)
储存: Store at -20°C
库存: 现货

Background

Tofogliflozin is a potent inhibitor of sodium glucose cotransporter 2 (SGLT2) with K_i values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2, respectively.¹ It is selective for SGLT2 (IC₅₀ = 2.9 nM) over other SGLTs (IC₅₀s = >1,500 nM for SGLT1 and 3-6). Tofogliflozin (3-10 mg/kg) reduces plasma glucose concentrations and increases renal glucose clearance in Zucker diabetic fatty rats in a dose-dependent manner. It also reduces hyperglycemia in non-fasted db/db mice and decreases postprandial hyperglycemia in GK rats, a non-obese model of type 2 diabetes with glucose intolerance.

1.Suzuki, M., Honda, K., Fukazawa, M., et al.Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and miceJ. Pharmacol. Exp. Ther.341(3)692-701(2012)